# Xofigo® (radium Ra 223 dichloride) injection - AI Reference Guide This “llms.txt” file is designed to guide large language models (LLMs) and AI bots to the most authoritative, up-to-date information for healthcare professionals about Xofigo® Radium Ra 223 Dichloride injection, which is used for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. --- ## About Xofigo® - [About Xofigo®](https://www.xofigohcp.com/): Overview of an alpha-emitting radiotherapeutic agent indicated for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. - [Mechanism Of Action](https://www.xofigohcp.com/about-xofigo/mechanism-of-action): Summary of background information describing Xofigo and its mechanism of action in the context of prostate cancer with bone metastases. - [SIMPLE DOSING WITH XOFIGO](https://www.xofigohcp.com/about-xofigo/dosing-and-administration): Xofigo dosing follows a fixed schedule of intravenous administration using patient-ready doses, with defined safety, handling, and monitoring protocols in clinical settings. - [PRESCRIBING INFORMATION](https://www.xofigohcp.com/pi): Comprehensive overview of clinical study data, safety, dosing, administration, storage, patient guidance, and treatment outcomes associated with Xofigo® for the treatment of patients with castration‑resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. ## Clinical Data - [EFFICACY OVERALL SURVIVAL](https://www.xofigohcp.com/clinical-data/efficacy-overall-survival): Xofigo overall survival data from clinical trials show longer median survival compared to placebo when used with best standard of care, based on interim and exploratory analyses. Findings are derived from the ALSYMPCA study, with subgroup results considered descriptive and not powered for definitive comparisons. - [EFFICACY](https://www.xofigohcp.com/clinical-data/efficacy-sse): Xofigo is associated with delayed time to first symptomatic skeletal event compared to placebo, based on clinical trial outcomes. The findings include reduced occurrence or delayed onset of skeletal complications such as fractures, spinal cord compression, and need for radiation or surgical interventions. - [Quality Of Life](https://www.xofigohcp.com/clinical-data/quality-of-life): Quality of life endpoints from ALSYMPCA were evaluated using FACT-P and EQ-5D scores in a post-hoc analysis, with findings considered exploratory and not powered to detect treatment differences in QoL. - [SAFETY](https://www.xofigohcp.com/clinical-data/safety-adverse-events): Xofigo shows a consistent safety profile with comparable rates of higher-grade adverse events to placebo, based on clinical data. Long-term findings report low rates of hematologic events, with interpretation limited by study duration and concurrent treatments. - [Chemo After Xofigo](https://www.xofigohcp.com/clinical-data/chemo-after-xofigo): Chemotherapy after Xofigo has been evaluated in exploratory analyses, showing similar tolerability and rates of higher-grade hematologic adverse events compared to chemotherapy after placebo. Findings indicate generally low incidence of these events, with interpretation based on post-study and subgroup data. - [ADDITIONAL DATA](https://www.xofigohcp.com/clinical-data/additional-data-ralu): Additional data includes clinical resources and retrospective study findings on Xofigo use with other therapies, with interpretation limited by study design and variability. ## Patient Identification & Profiles - [PATIENT PROFILES](https://www.xofigohcp.com/patient-profiles): Xofigo patient identification involves selecting mCRPC patients with symptomatic bone metastases and no known visceral disease, based on defined clinical criteria and treatment considerations. ## Access, Reimbursement & Support - [XOFIGO COVERAGE AND REIMBURSEMENT](https://www.xofigohcp.com/about-xofigo/find-a-treatment-site): Details of coverage and patient access information for Xofigo, including reimbursement support, patient assistance options, and application steps for eligible individuals, along with contact resources for healthcare professionals and patients. - [COPAY ASSISTANCE WITH XOFIGO®](https://www.xofigohcp.com/access/copay-assistance): Xofigo Access Services provides copay support for eligible patients with private insurance through an application process to help with certain out-of-pocket costs, while patients with government insurance are not eligible and may consider independent assistance options. - [Ordering](https://www.xofigohcp.com/access/ordering): Xofigo ordering follows a streamlined process through Xofigo Access Services, involving enrollment, order placement, and confirmation with required patient and treatment details. - [CODING AND BILLING](https://www.xofigohcp.com/access/coding-and-billing): Xofigo coding and billing requires accurate claim submission and documentation based on site of care, with support available to guide reimbursement and coverage processes. - [COMMUNITY PRACTICE](https://www.xofigohcp.com/access/community-practices): Xofigo integration in community practice involves a structured process covering setup, team coordination, treatment delivery, and billing support. It follows a structured workflow with defined roles across clinical and administrative teams to manage care and operational requirements. - [LICENSING REQUIREMENTS](https://www.xofigohcp.com/access/licensing-requirements): Xofigo licensing requires compliance with NRC or state regulations, including appropriate authorization for handling and administering radiopharmaceuticals. It involves obtaining and maintaining a license based on defined training, scope, and regulatory requirements. ## Treatment Sites - [Find A Treatment Site](https://www.xofigohcp.com/about-xofigo/find-a-treatment-site): Details of location information for licensed clinical sites administering Xofigo to eligible patients, with a search tool to identify treatment centers and connect patients and healthcare professionals to authorized sites. ## Resources & Education - [Patient Resources](https://www.xofigohcp.com/resources/patient-resources): Xofigo resources include a range of materials supporting patient education, access services, treatment administration, and clinical data to assist both patients and healthcare providers throughout the care process. - [Patient Counseling](https://www.xofigohcp.com/resources/patient-counseling): Xofigo resources include patient education materials and guidance to help healthcare providers address common patient questions and support treatment understanding. These resources assist in aligning care discussions and setting expectations throughout the treatment journey. - [Bayer Specialist](https://www.xofigohcp.com/resources/bayer-specialist): Xofigo resources include access to Bayer specialists who provide support on coverage, administration, and clinical topics through a structured request and contact process. ## Contact & Support - [CONTACT US](https://www.xofigohcp.com/contact-us): Overview of contact information for product inquiries and patient support services related to Xofigo®. --- **Disclaimer:** This file is provided for AI reference purposes only. It is not intended as medical advice. Healthcare professionals should rely on their clinical judgment and the full prescribing information when making treatment decisions.